Company news

Theriva Biologics, Inc. news in 2026

Theriva Biologics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Theriva™ Biologics Announces Reverse Stock Split

November 20, 2026

Theriva™ Biologics Reports Third Quarter 2026 Operational Highlights and Financial Results

November 12, 2026

Theriva™ Biologics Announces Sale of SYN-004 (ribaxamase) and Related Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc.

November 2, 2026

Theriva Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results

August 12, 2026

Theriva Biologics: Q2 Earnings Snapshot

August 11, 2026

Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results

August 11, 2026

Theriva Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma

August 7, 2026

Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma

August 6, 2026

Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma

July 7, 2026

Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results

May 5, 2026

Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting

April 17, 2026

Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma

March 23, 2026

Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results

March 12, 2026

Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications

February 18, 2026

Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026

February 3, 2026

Decks in 2026